Table 2 Correlation between number of ranibizumab injections and candidate variables (all countries; over 2 years)
Parameters | Year 1 | Year 2 | ||
|---|---|---|---|---|
Coefficient a | P-value | Coefficient a | P-value | |
Age at start of therapy | –0.0289 | 0.1141 | –0.0378 | 0.056 |
Sex | 0.0171 | 0.384 | –0.0126 | 0.5193 |
Health insurance (public) | –0.028 | 0.1544 | –0.053 | 0.0071 |
Reimbursement type (national standards) | 0.1297 | <0.001 | 0.1524 | <0.001 |
Medical history (prior disease) | –0.0268 | 0.1711 | –0.0354 | 0.0703 |
Medical history (concomitant disease) | –0.0003 | 0.9866 | 0.018 | 0.3595 |
Medical history (ocular disease) | –0.0246 | 0.2083 | –0.0331 | 0.0905 |
Baseline VAS | –0.0088 | 0.6758 | 0.0424 | 0.0444 |
Treatment duration | 0.5645 | <0.001 | 0.7389 | <0.001 |
Switch to other treatments | 0.0275 | 0.1599 | 0.0632 | 0.0012 |
Baseline presence of retinal breaksb | NA | NA | NA | NA |
Baseline presence of pigment epithelial detachment | 0.0821 | 0.0038 | 0.1163 | <0.001 |
Number of ophthalmoscopies | 0.2499 | <0.001 | 0.3425 | <0.001 |
Optical coherence tomography, n | 0.3777 | <0.001 | 0.4955 | <0.001 |
Fluorescein angiography, n | 0.0509 | 0.0093 | 0.1154 | <0.001 |
ICGA, n | –0.0341 | 0.0814 | 0.0302 | 0.1228 |
Ophthalmoscopies/optical coherence tomography, n | 0.3608 | <0.001 | 0.4673 | <0.001 |
Number of monitoring visits | –0.1349 | <0.001 | 0.0239 | 0.2224 |
